Molecular genetics of supratentorial primitive neuroectodermal tumors and pineoblastoma

MEI HUA LI, PH.D., ERIC BOUFFET, M.D., CYNTHIA E. HAWKINS, M.D., PH.D., JEREMY A. SQUIRE, PH.D., AND ANNIE HUANG, M.D., PH.D.

Arthur and Sonia Labatt Brain Tumor Research Centre, Cancer Research Program, Division of Hematology and Oncology, and Department of Pediatric Laboratory Medicine, Hospital for Sick Children, Toronto; Ontario Cancer Institute, Toronto; and Department of Pathobiology and Laboratory Medicine, University of Toronto, Ontario, Canada

The supratentorial primitive neuroectodermal tumors (PNETs) are a group of highly malignant lesions primarily affecting young children. Although these tumors are histologically indistinguishable from infratentorial medulloblastoma, they often respond poorly to medulloblastoma-specific therapy. Indeed, existing molecular genetic studies indicate that supratentorial PNETs have transcriptional and cytogenetic profiles that are different from those of medulloblastomas, thus pointing to unique biological derivation for the supratentorial PNET. Due to the rarity of these tumors and disagreement about their histopathological diagnoses, very little is known about the molecular characteristics of the supratentorial PNET. Clearly, future concerted efforts to characterize the molecular features of these rare tumors will be necessary for development of more effective supratentorial PNET treatment protocols and appropriate disease models. In this article the authors review existing molecular genetic data derived from human and mouse studies, with the aim of providing some insight into the putative histogenesis of these rare tumors and the underlying transforming pathways that drive their development. Studies of the related but distinct pineoblastoma PNET are also reviewed.

KEY WORDS • supratentorial primitive neuroectodermal tumor • pineoblastoma • molecular genetics

OVERVIEW

The supratentorial PNET and pineoblastoma are high-grade, relatively undifferentiated tumors arising from the cerebral hemispheres and the pineal regions, respectively. Although they are histologically very similar to medulloblastoma, supratentorial PNETs have markedly different clinical behavior and are generally considered to represent a more aggressive tumor group than medulloblastoma, with a frequently massive tumor burden and a higher incidence of disseminated disease at diagnosis, as reviewed in Jakacki.95 Because cerebral supratentorial PNETs may often be deep-seated in paraventricular, thalamic, and hypothalamic sites,44 they pose significant challenges to safe resection and the delivery of limited radiation. Thus, despite their smaller numbers, supratentorial PNETs are a significant therapeutic problem because these highly aggressive, therapy-resistant tumors primarily affect younger children, who are the most likely to suffer long-term damage due to radiation. Existing data support the suggestion that supratentorial PNETs have molecular features that are unique from those of medulloblastoma. Nevertheless, because of the rarity of supratentorial PNETs, only limited molecular studies of small numbers of supratentorial PNETs have been conducted to date. Clearly, comprehensive knowledge of the molecular genetic features of supratentorial PNETs will be essential in future studies to advance diagnosis, therapy, and prognosis in this rare but challenging tumor group. We review existing molecular studies of supratentorial PNETs with a view to improving our current understanding of putative signaling defects and molecular abnormalities in supratentorial PNETs. We also review molecular studies of pineoblastomas, a WHO94 Grade IV pineal parenchymal tumor that has often been considered collectively with the supratentorial PNET in molecular and therapeutic studies. Nevertheless, existing data suggest distinct histogenesis and unique molecular genetics for the pineoblastoma, and they are therefore discussed separately.
are diagnosed at a younger median age than medulloblastomas; more than 65% of supratentorial PNETs are reported in patients younger than 5 years of age with no significant sex predominance (reviewed in Jakacki, et al.\textsuperscript{91}). In a Pediatric Oncology group trial for delayed radiation in children younger than 3 years of age, supratentorial PNETs represented the second most common tumor (13 of 19).\textsuperscript{44} Supratentorial PNETs can present as congenital tumors.\textsuperscript{9,64,113} Although supratentorial PNET is generally considered almost exclusively a pediatric tumor, rare adult series have been described.\textsuperscript{91,155} There is currently insufficient literature to judge whether supratentorial PNETs in adults differ from those in children. It is notable, however, that one study reported a 3-year survival rate of 75% for a series of 12 patients, a rate far superior to any reported in pediatric supratentorial PNETs.\textsuperscript{91} These observations, together with reports of a high frequency of p53 mutations in adult supratentorial PNETs,\textsuperscript{74} suggest they are likely to represent distinct diseases.

High-grade glial tumors are well recognized as potential late complications of the craniospinal radiation treatment used in childhood leukemias. Interestingly, supratentorial PNETs can also present as secondary malignancies after therapy for hematological as well as primary intracranial neoplasms. To date, seven cases of secondary supratentorial PNET arising after treatment for childhood acute lymphocytic leukemia, acute myeloid leukemia, or lymphoma have been reported.\textsuperscript{102} Secondary supratentorial PNETs have been reported in the context of cancer predisposition syndrome in two patients. One child presented with supratentorial PNET 5 years after treatment for unilateral retinoblastoma,\textsuperscript{50} and in another with neurofibromatosis Type 1, supratentorial PNET developed after radiation treatment for a brainstem astrocytoma.\textsuperscript{132} Supratentorial PNETs can also occur as secondary malignancies in both children and adults with no genetic condition. Tumors occurring up to 18 years after radiation treatment for low-grade primary intracranial neoplasms such as cerebellar pilocytic astrocytoma and low-grade astrocytoma have been described.\textsuperscript{34,69}

A supratentorial PNET most commonly arises in the cerebrum, and is seen less frequently in deep paraventricular or midline locations such as the diencephalon and basal ganglia.\textsuperscript{47} Rarely, PNETs can present in the leptomeninges without evidence of primary tumor in the supratentorial compartments.\textsuperscript{12} These are proposed to arise from heterotopic glial nests within the subarachnoid space; however, their true histogenesis and their relationship to either medulloblastoma or supratentorial PNET is unknown.

The current literature contains reports suggesting that metastatic disease, extent of surgery, and age at diagnosis may be of prognostic relevance in supratentorial PNETs.\textsuperscript{3,75,135} Based on more aggressive clinical features, supratentorial PNETs have traditionally received therapies designed for metastatic, high-risk medulloblastomas, which involves more intensive chemotherapy and higher doses of radiation to the head and spine. Several retrospective\textsuperscript{123,135} and prospective studies\textsuperscript{40,75,86} have consistently reported significantly inferior outcomes for even localized supratentorial PNETs treated with high-risk medulloblastoma therapy. To date, the overall survival rate for supratentorial PNETs is substantially lower than that for medulloblastomas, with an expected 3-year progression-free survival of approximately 50% for localized supratentorial PNETs.\textsuperscript{75,138} These observations suggest intrinsic biological differences between supratentorial PNET and medulloblastoma.

**Histopathological Diagnosis of Supratentorial PNET**

Histopathological classification of supratentorial PNET remains a contentious issue. Based on the indistinguishable histological features of supratentorial PNET and medulloblastoma, a common histopathological grouping of all PNETs with a presumed common histogenesis was proposed\textsuperscript{40} and remains disputed.\textsuperscript{109} Current WHO criteria identify supratentorial PNET as a Grade IV tumor with undifferentiated or poorly differentiated neuroepithelial cells, and with the capacity for divergent differentiation along multiple lineages, including neuronal, astrocytic, ependymal, muscular, or melanocytic lines.\textsuperscript{142} Because specific marker(s) for supratentorial PNET do not exist, these lesions are still diagnosed primarily on the basis of a supratentorial location and histological features of a predominantly undifferentiated neuroepithelial tumor with focal areas of divergent differentiation. The inclusion of supratentorial neuronal tumors with more distinct neuronal differentiation, such as the cerebral neuroblastoma, or the ganglioneuroblastoma with its distinct ganglionic features, remains controversial.\textsuperscript{12,134} When supratentorial PNETs demonstrate very little morphological or immunohistochemical signs of differentiation, they pose diagnostic challenges with respect to other high-grade supratentorial tumors such as the “round” or “small cell” glioblastoma variants, which may also exhibit a similarly undifferentiated phenotype.\textsuperscript{94} For polyphenotypic supratentorial PNETs presenting in a young child with expression of epithelial or muscular antigens such as epithelial membrane antigen and smooth-muscle actin, the differentiation from the highly aggressive CNS rhabdoid tumors\textsuperscript{141} may pose significant challenges, because INI1 mutation has been reported in supratentorial tumors without typical histological “rhabdoid” features.\textsuperscript{150}

In a recent survey, pathologists identified histopathological diagnosis of supratentorial PNET as an area of significant challenge.\textsuperscript{7} The continuing uncertainties about the precise histological criteria required for diagnosis and the relative rarity of these tumors means that published genetic and molecular genetic data, particularly in small series, may be difficult to interpret, and may have included high-grade neuroglial and neuroepithelial tumors whose histogenetic relationships to supratentorial PNETs were uncertain. Nonetheless, molecular cytogenetic data compiled so far suggest that supratentorial PNETs collectively exhibit changes that differ from those of the infratentorial medulloblastoma.\textsuperscript{115,146} and support the development of supratentorial PNETs from biological pathways distinct from those involved in medulloblastoma development.

**Cytogenetic and Molecular Genetic Alterations in Human Supratentorial PNETs**

In contrast to medulloblastomas, very few cytogenetic and molecular genetic studies of human supratentorial PNETs are available. To date, karyotypic studies of only 22 pediatric supratentorial PNETs arising in the cerebrum have been reported as part of larger collective series on medulloblastomas and PNETs\textsuperscript{1,11,15,21,30,32,61,139,162} (Table 1). Supratentorial PNETs frequently show complex karyotypes, with evidence of double minutes structures associated with high-
level gene amplification. Interestingly, eight of 19 reported cases had normal karyotypes. In one series of four infants with supratentorial PNET, three cases had normal karyotypes, whereas one case had monosomy as the sole cytogenetic abnormality, indicating that subtle genetic changes may be characteristic of a substantial proportion of supratentorial PNETs. Complex karyotypes in 10 of 19 cases involved mostly structural changes with interstitial deletions, partial chromosome gains, and translocations involving a number of different chromosomes. Recurrent regions of cytogenetic alterations included deletions or translocations involving chromosome 10q22-26 in three of 10 cases, and translocations involving chromosome 6q21-25 in two of 10.

Notably, one patient (Case 11 in Table 1) had a translocation involving chromosome 6q25 and chromosome 13q14 as the sole cytogenetic abnormality, which was a child with no history of retinoblastoma. The finding of this sole abnormality, also confirmed by the authors using high-resolution spectral karyotyping analyses, implies involvement of the RB1 locus on chromosome 13q14, and a putative novel supratentorial PNET oncogene or tumor suppressor gene at chromosome 6q21-25. No data were available on the constitutional DNA of this patient. Double minutes, indicative of high-level gene amplification, were seen in three of 18 cases, a frequency comparable to that reported for medulloblastoma. 

**Comparative Genomic Hybridization Studies**

The CGH profiles of 16 supratentorial PNETs (five of which were found in adults but not separately identified) are summarized in Fig. 1. Not surprisingly, these higher-resolution analyses indicate a greater frequency of genomic imbalances than appreciated on karyotypic studies, with only one of 16 supratentorial PNETs being reported as normal based on results of CGH. Existing data indicate that supratentorial PNETs differ from medulloblastomas in the pattern and frequency of DNA copy number changes. Most significantly, chromosome 17p loss, which characterizes many medulloblastomas, is observed. Of chromosome 17 is seen in supratentorial PNETs. In up to 40% of medulloblastomas, a characteristic isochromosome 17, which results from concurrent gain of chromosome 17q and loss of 17p, is observed. In contrast, although gain of 17q or the entire chromosome 17 is seen in supratentorial PNET, isochromosome 17 has only been reported in one case of supratentorial PNET. So far, allelotyping studies have disclosed loss of chromosome 17p in only one of 36 primary supratentorial PNETs and one supratentorial PNET cell line.
region on chromosome 17p11.2, which is presumed to inactivate a putative tumor suppressor in approximately 30% of medulloblastomas, is not seen in supratentorial PNETs.

Higher frequency and greater complexity of DNA copy number changes are reported in supratentorial PNETs compared with medulloblastomas. In one of the largest studies of 17 pediatric supratentorial PNETs, in which high-resolution CGH was used,130 genomic imbalance was reported in 70% of tumors, with a median of four changes per tumor. Most changes (63%) involved whole chromosomes, with partial chromosome imbalance seen in 37% of tumors.

Collectively, supratentorial PNETs exhibit a greater frequency of chromosome loss than gain. Distal chromosome 4q loss is the most frequent change, and is observed in up to 50% of the supratentorial PNETs studied.

Other regions of loss observed at significant frequency include chromosome 9 centering around distal 9p, and chromosomes 13q, and 14q. Less frequently, losses involving all or part of chromosomes 5, 6, 10q, 12, 18q, and 19q are reported. Interestingly, an isolated 3p21 interstitial deletion has been reported in one tumor;135 it remains to be determined whether the hMLH1 DNA repair gene mapping to this site is involved. Losses of chromosome 10q observed in approximately 25% of supratentorial PNETs appear to involve the known tumor suppressors BTRC,173 PTEN, or DMBT1 only rarely, with only one mutation reported in 21H.98 and nine supratentorial PNETs85 for PTEN and DMBT1, respectively. The DLC-1, a putative tumor suppressor on chromosome 8p22, is epigenetically inactivated in one of three supratentorial PNETs.141 Clearly, further studies are needed to determine the nature of putative supratentorial PNET tumor suppressor loci associated with DNA copy number losses and their mechanisms of gene inactivation in supratentorial PNETs.

Similar to observations in medulloblastomas,8,17 gains at chromosome 7 (six of 16), followed by 1q, occur most frequently in supratentorial PNETs. Gains of chromosomes 9pter, 13, and 17 have been reported in more than one case. Consistent with detection of double minutes in karyotypic studies, CGH analyses of supratentorial PNETs have identified high-level DNA amplification at chromosomes 2p24, 4q12-13, 7q21.3, and 7p11.2. Additional amplicons at chromosomes 1q, 6p, 12q12.1, 6p, and 20q have been reported.135 With the exception of the chromosome 2p24 amplification, which has been shown to be related to N-myc gene amplification,11 the majority of putative oncogenic loci indicated by cytogenetic findings in supratentorial PNETs remain unknown. Studies with higher-resolution single gene mapping tools (such as the recently developed array-based CGH technology35 and with larger tumor numbers will be very valuable for defining the true spectrum and frequency of genomic imbalances, and to locate oncogenes and tumor suppressor genes that underlie supratentorial PNET development.

Developmental Signaling Pathways in Supratentorial PNETs

Based on the relatively primitive histological features of these tumors, it has long been postulated that PNETs of the CNS (supratentorial PNET and medulloblastoma), arise
Molecular genetics of supratentorial PNETs and pineoblastomas

from transformation of periventricular germinal matrix cells.159 Nevertheless, studies of murine models and primary human tumors have now demonstrated that some medulloblastomas can arise from germinal cells in the external granular layer of the cerebellum.155 Recently, a microarray-based study in which the expression profiles of eight supratentorial PNETs were compared with those of normal human cerebellum and medulloblastoma, showed that supratentorial PNETs have transcriptional signatures distinguishable from those of normal fetal cerebellum and medulloblastoma. In particular, medulloblastoma and supratentorial PNET differentially express cerebellar granule cell–specific transcription factors like ZIC1 and NSCL127 supporting a cerebellar granule cell origin for medulloblastomas but not supratentorial PNETs. Although the cell of origin in supratentorial PNETs is not known, their putative derivation from cells of periventricular germinal matrix is suggested by the frequent clinical presentations of these tumors from deep periventricular locations. Histopathological studies of human pineal and midbrain tumors156 as well as studies of transgenic mice with midbrain PNET,157 also indicate that subependymal cells of the diencephalon are likely to be targets of transformation in supratentorial PNETs.

There is now overwhelming evidence that developmental signaling pathways that control normal brain development are dysregulated by tumor-specific mutations in medulloblastomas.154 Current evidence suggests that the Shh–Gli, Notch, and to a lesser extent Wnt (or Wingless) signaling pathways may also be involved in supratentorial PNET development.

The Shh–Gli Pathway. Extensive studies have now established a clear role for Shh signaling in normal and malignant cerebellar development. In addition, studies of human tumors and mouse models have shown that abnormal Shh signaling contributes to development of a proportion of medulloblastomas. Specifically, mutations in the PTCH, SMO, and SUFU genes, leading to pathological Shh pathway activation have been demonstrated in a proportion of syndrome-associated and sporadic medulloblastomas. The Shh–Gli pathway is reviewed in detail in the article by Taylor, et al.,154 and thus only salient features are outlined here.

The role of Shh signaling in development of the cerebral cortex and the corresponding malignant tumors, such as supratentorial PNET and gliomas, has not been extensively investigated. The Ptc1 mutant mice, even in a p53-deficient background, have not been reported to develop supratentorial PNETs.156 Nevertheless, recent studies indicate that Shh may also serve important mitogenic functions in the developing mouse cortex. Specifically, Dahmane, et al.,158 demonstrated expression of all three Gli proteins (Gli1–Gli3), which are downstream effectors of Shh signaling, in the ventricular and subventricular zone of the perinatal murine cerebral cortex and midbrain. They observed that Shh had mitogenic effects on nestin-positive neocortical precursors and cells of the ventricular zone, and could induce Gli1 in the latter cell population. These findings thus indicate that in addition to its role in cerebellar development, the Shh–Gli pathway may also control the development of dorsal brain/cerebral cortical growth, and contribute to the development of corresponding tumors, such as supratentorial PNET.

Due to the rarity of supratentorial PNETs, the status of the Shh–Gli signaling pathway in supratentorial PNETs remains incompletely investigated, and has generally only been reported collectively with medulloblastoma. Limited studies of supratentorial PNET tumors to date indicate however, that the Shh–Gli pathway is active, and may be altered, in a proportion of supratentorial PNETs. Specifically, expression of Gli1, Gli3, and Ptc1 transcript has been reported in one supratentorial PNET.159 Increased expression of PTCH, SMO, and GLI1 mRNA has been observed in three to five of five supratentorial PNETs studied.160 In addition, all supratentorial PNET tumors in a small series of three were reported to express N-myc, a known downstream target of Shh signaling, according to immunohistochemistry studies.159 Missense mutation172 as well as loss of heterozygosity164 involving the ptc locus at chromosome 9q22.3 has also been reported in three of eight pediatric supratentorial PNETs studied. The functional implications of these molecular findings need to be further validated in appropriate tumor models. Nonetheless, these limited studies indicate that Shh–Gli1 pathway aberrations are likely to have a pathogenetic role in at least a proportion of supratentorial PNETs. The scope of Shh–Gli1 pathway involvement in supratentorial PNET, and whether they correlate with any specific histopathological features in these tumors must await studies conducted in larger numbers of tumors.

Notch–Hes Signaling. Experimental evidence from murine studies indicates that the Notch signaling pathway plays an important role in regulating normal neurogenesis by restricting neuronal differentiation and promoting maintenance of progenitor cells.83 Notch family genes encode large transmembrane proteins (Notch 1–4) with extracellular endothelial growth factor–like repeats that act as receptors for membrane-bound ligands (Jagged, delta) expressed by neighboring cells (Fig. 2). Current evidence supports the proposition that Notch signaling may act negatively or positively to regulate cellular proliferation or differentiation depending on the cell context. Notch signaling is activated by ligand binding and involves complex cleavage and release of an intracellular Notch fragment (the Notch intracellular domain), which translocates to the nucleus. The Notch intracellular domain heterodimerizes with the DNA binding transcription factor CBP1 to activate target genes of the Hes (1–5) family. The best-characterized Notch effector, Hes 1, negatively regulates basic helix-loop-helix neurogenic transcription activators such as hASH1.58,153 The Hes 1 is highly expressed in the ventricular zone of the developing nervous system, and misexpression of Hes 1 has been shown to prevent neural differentiation.83,157

Aberrant Notch signaling has been linked to a spectrum of human malignancies including T-cell leukemia, in which a t(7;9) translocation results in a constitutively active and oncogenic Notch 1 molecule (see review by Allenspach, et al.). Investigations of Notch signaling in PNETs and medulloblastomas of the CNS are at an early stage, with only a few studies reported to date. These studies, however, demonstrate evidence of Notch pathway activation in PNETs of the CNS, and differential expression of Notch pathway components in medulloblastoma and supratentorial PNETs, perhaps reflecting distinct cells of origin for these tumors. In one study of 13 medulloblastomas and five supratentorial PNETs, hASH1 expression was seen in three of five
supratentorial PNETs and none of 12 medulloblastomas, whereas expression of NeuroD genes appeared to be more prevalent in medulloblastomas.

A more recent study has shown differential expression of Notch1 and Notch 2 in supratentorial PNETs compared with medulloblastomas, with a greater prevalence of high Notch 2 expression in supratentorial PNETs. Indeed, more than 50% of supratentorial PNETs, including a supratentorial PNET cell line, expressed extremely high levels of Notch 2 mRNA, whereas both primary medulloblastomas and two cell lines expressed Notch 2 and Notch 1 at levels comparable to control cerebellar cells. Significantly, three of six tumors with high Notch 2 mRNA had genomic amplification or copy number gains of the Notch 2 locus on chromosome 1p11-13, and Notch 2 knockdown in PFSK, a supratentorial PNET cell line, resulted in inhibition of cell growth, thus supporting a functional role for Notch 2 in supratentorial PNET. Interestingly, a second study has reported more frequent Notch 1 than Notch 2 overexpression in medulloblastoma mice with targeted overexpression of the Shh pathway gene (Smo) to the cerebellar external granule layer through a NeuroD2 promoter suggest crosstalk between Notch and Shh signaling in medulloblastoma. Whether the same will hold true in supratentorial PNET remains to be seen.

The Wnt Pathway. The Wnt (or Wingless) pathway is a highly conserved signaling pathway with a key role in control of cellular proliferation, differentiation, migration, and adhesion. A role for Wnt signaling in brain tumor development was first recognized through studies of Turcot syndrome, a heritable association of CNS neuroepithelial tumors and adenomatous polyposis of the large intestine caused by germ line mutations of the APC gene.

The APC protein normally exists as part of a large degradative protein complex that includes Axin, GSK-3β, and β-catenin. This protein tightly regulates the subcellular location and function of β-catenin, a key transcriptional effector of Wnt signaling. In the context of appropriate growth or differentiation signals, Wnt signaling is activated by ligand binding to Frizzled transmembrane receptors, which triggers degradation of GSK3β and consequently inactivates the APC complex. In the absence of degradative signals, accumulated cytosolic β-catenin translocates to the nucleus, and acts with TCF transcription factors to activate target genes, which include the c-myc oncogene. The β-catenin also acts to regulate cell adhesion by associating...
Molecular genetics of supratentorial PNETs and pineoblastomas

with membrane-bound cadherin proteins. Tumor-specific mutations of Wnt pathway components have been described in medulloblastomas, in which c-myc and N-myc activation are reported in a substantial proportion of tumors.4,52

The Wnt pathway aberrations have not been extensively investigated in supratentorial PNETs. Single β-catenin mutation was reported in a small study of four supratentorial PNETs.95 This mutation, which resulted in a somatic Gly to Val change within a protein degradation targeting signal in exon 3, correlated with β-catenin nuclear accumulation and Wnt activation. Increased expression of c-myc and N-Myc, a downstream β-catenin target, has been reported in supratentorial PNET cell lines,90 suggesting potential etiological roles for the Wnt pathway in supratentorial PNET development. Nevertheless, further studies are needed to assess the prevalence of Wnt pathway aberrations in supratentorial PNET.

Tumor Suppressor Loci in Supratentorial PNETs

Genomic mapping studies indicate a putative supratentorial PNET suppressor loci on chromosomes 4q, 9p, 13, and 14q, in which DNA copy number losses are most often observed.115,130,146 The identities of these putative loci remain to be determined. Known tumor suppressor pathways with evidence of involvement in supratentorial PNET development are discussed later.

The p53 Locus. The p53 tumor suppressor locus on chromosome 17p13.1 is one of the most frequently mutated genes in human cancers. Nullizygous p53 mice are viable but highly susceptible to tumor development.49 In humans, germ-line p53 mutations result in the Li-Fraumeni syndrome, a rare heritable cancer syndrome associated with diverse malignancies, including brain tumors.105 A key cellular function of p53 (extensively reviewed in Bourdon, et al.26) is to inhibit malignant cell transformation resulting from events such as DNA damage or ectopic oncogene expression, by induction of genes involved in cell cycle arrest and apoptosis. Most p53 mutations in human cancers result in structural alterations with loss of wild-type p53 growth inhibitory functions and may also generate mutant p53 proteins with dominant negative properties or gain of new biochemical and biological functions that promote malignant cell growth.28 Due to its central role in controlling cell growth, p53 function is normally tightly regulated by a variety of cellular mechanisms that may also be targeted in tumor cells.63 These include amplification of the MDM2 oncogene on chromosome 12q14, a ubiquitin ligase that facilitates proteosomal degradation of p53. Loss of p15ARF, a critical upstream activator of p53,51 can also represent a common mechanism of functional p53 loss in tumors (described in the following section).

Supratentorial PNET as well as medulloblastoma have been described in familial Li-Fraumeni syndrome,166 but because PNETs of the CNS were described collectively,48,56,179 the specific incidence of either tumor type in Li-Fraumeni syndrome is not known. Germ line p53 mutations described in supratentorial PNETs involve codon 213, and an unusual CAT to AAT transversion in codon 179,129 suggesting the possibility of other atypical p53 mutations in supratentorial PNET.

Although p53 mutations are estimated to occur in approximately 27% of all brain tumors,143 these mutations occur rarely (< 1%) in sporadic malignant pediatric brain tumors.128 The relative lack of p53 mutations in pediatric brain tumors have been corroborated by individual studies of pediatric supratentorial PNETs. Mutational studies of a sum of 28 pediatric supratentorial PNETs in four separate studies30,74,99,133 have identified only one somatic p53 mutation.98 Interestingly, in a study of 14 adult and pediatric cerebral PNETs, p53 mutations were observed in six of 11 cases in adults and none of three pediatric supratentorial PNETs.74 These observations lead us to suggest that, similarly to pediatric high-grade gliomas,138 childhood supratentorial PNETs may differ genetically from the corresponding tumors in adults.

Despite the rarity of p53 mutations in sporadic supratentorial PNET, a role for this gene in supratentorial PNET pathogenesis is suggested by development of supratentorial PNET in several p53−/− murine brain tumor models,158,177 and in SV40 T antigen–driven transgenic PNET models.2,107 In addition, high p53 protein expression, indicative of p53 dysfunction, is seen in a significant proportion of supratentorial PNETs.31,51,87,174 The true frequency of p53 immunopositivity in supratentorial PNETs is not known because studies have often considered medulloblastoma and supratentorial PNET collectively. Nevertheless, studies of 12 cases of supratentorial PNET in two small series (one included three medulloepitheliomas) suggested that up to 90% of supratentorial PNETs display p53 dysfunction, as indicated by strong p53 positivity.51,137 In contrast, strong p53 immunopositivity is reported in 10 to 30% of medulloblastomas.51,134 Correlation of p53 mutations was not conducted in these studies; thus the mechanisms for p53 immunopositivity in these tumors are not known. Studies conducted in a small number of tumors indicate that mdm2 amplification may not be a common mechanism for p53 loss in supratentorial PNETs. Mutually exclusive mutations in p53, methylation of p14ARF, or deletion of INK4/ARF, have recently been demonstrated in up to 25% of medulloblastomas.56 Thus, a greater role for p53 and p53 regulatory pathways in supratentorial PNET development may yet be demonstrated.

Recently, several novel members of the p53 protein family (p63 and p73) that have roles in oncogenesis have been identified.92 In addition, p53 isoforms resulting from alternative splicing have also been reported.23 The significance of these novel p53 family members/isoforms in supratentorial PNET development remains to be investigated.

The INK4/ARF Pathway. The cdk/INK4/pRB pathway is a key mediator of mitogenic and antimitogenic signals necessary for normal cellular proliferation. Not surprisingly, this pathway is deregulated in more than 80% of human tumors by genetic and epigenetic alterations of different components, as reviewed in various studies (Fig. 3).10,114,151

The INK4a/ARF locus on chromosome 9p21 encodes two distinct tumor suppressor proteins (p16INK4a and p15ARF), which normally act in parallel to regulate the function of the pRB and p53 tumor suppressors, respectively. In normal cells, wild-type P16INK4a maintains the pRB tumor suppressing function by inhibition of cdk4 and cdk6 activity, resulting in pRB hypophosphorylation, E2F repression, and induction of G1 arrest. In tumor cells, deletions or mutations of p16INK4a renders it ineffective for regulation of cdk4/6 activity, resulting in pRB hyperphos-
phorylation, loss of E2F repression, and activation of genes permissive for G₁–S phase transitions and unregulated cellular proliferation. Under normal cellular growth conditions, p15ARF acts to stabilize p53 by binding to MDM2. Loss of P15ARF function through genetic and epigenetic mechanisms in tumor cells results in functional loss of p53, as reviewed in Roussel and Sherr.

The INK4 proteins (a–d) are highly conserved and have partly redundant functions that remain incompletely elucidated. Like INK4a and b, the INK4c and d proteins regulate pRB function by specifically inhibiting cdk4 and cdk6 activity. Unlike P15INK4b and P16INK4a, however, the P18INK4c and/or P19INK4d show temporal and spatial expression in the developing and mature brain, leading to the suggestion that these proteins may have context-specific tumor suppressor functions. Loss of Ink4c/d or p53 alone do not predispose mice to brain tumors. Nevertheless, Zindy, et al., described a spectrum of tumors, including brain tumors in p53 null mice with homozygous loss of Ink4c or Ink4d. Mice with homozygous or heterozygous loss of Ink4c developed cerebellar tumors resembling medulloblastoma. Interestingly, mice with only Ink4d loss developed cerebral tumors resembling human supratentorial PNET. In addition to cerebellar tumors, mice heterozygous for Ink4d and Ink4c developed supratentorial PNET-like tumors originating from periventricular zones and thalamic locations. It is noteworthy that Ink4d is normally expressed in the progenitor cells of the rat telencephalon and neonatal subventricular zone, and that it has been implicated in inhibition of postnatal neuronal differentiation. These observations indicate cooperative tumorigenic effects of p53 and the INK4c and INK4d proteins, and perhaps a more specific requirement for INK4d inactivation in supratentorial PNET development.

As described in the preceding section, there is evidence of p53 dysfunction in a substantial proportion of supratentorial PNETs studied to date. The status of the INK4/ARF and cdk4/6 loci has not been specifically investigated in supratentorial PNET. It is significant that although only rare p16 deletions in medulloblastoma had been identified in previous studies, more recent reports demonstrate that up to 25% of the large cell aggressive variant of medulloblastoma show evidence of genetic or epigenetic lesions in the INK4/ARF/p53 pathway. It is interesting that in the study by Zindy, et al., mice heterozygous for both Ink4c and Ink4d developed both medulloblastoma and midline supratentorial PNET–like tumors, thus raising the possibility that a spectrum of medulloblastoma, such as the anaplastic variant, may share etiological pathways with supratentorial PNETs.

The PMS2 Pathway. Both medulloblastoma and supratentorial PNET have been linked to Turcot syndrome, which is characterized by concurrence of primary brain tumor and multiple colorectal adenomas. Two types of syndromes are recognized: Turcot Type 2 occurs in the setting of familial adenomatous polyposis and involves germ line mutations of the APC gene on chromosome 5q21. The predominant brain tumor in Turcot Type 2 is medulloblastoma, in which syndrome-associated mutations in APC or beta-catenin mutations have been demonstrated. Turcot Type 1 comprises a second syndrome with clinical findings of nonfamilial adenomatous polyposis–associated colorectal cancer (hereditary nonpolyposis colorectal cancer), skin lesions (including café-au-lait spots–), and glioblastoma. It is a genetically heterogeneous disease resulting from germ-line defects in several DNA mismatch repair genes, including hMLH1 (3p21 locus), hMSH2 (2p16), hMSH3 (5q11-q13), hMSH6 (2p16), hPMS1 (2q31), and hPMS2 (7p22). Defects in these loci lead to genetic instability in which short repeated sequences (microsatellites) are characteristically altered due to accumulation of unrepaired somatic mutations. The PMS2 and hMLH1 gene products form heterodimers and provide one of the major DNA mismatch repair activities in mammalian cells. Although MLH1 mutations are commonly seen in hereditary nonpolyposis colorectal cancer, germ-line mutations of PMS2 have been described only recently. De Vos, et al., reported on two siblings with supratentorial PNETs in a heavily consanguineous family with cosegregation of learning difficulties, cutaneous café-au-lait spots, and early-onset brain tumors inherited in a recessive fashion. A homozygous missense mutation in exon 14 of PMS2 leading to protein truncation was demonstrated in all affected individuals.

In addition to the detection of germ line PMS2 mutations in supratentorial PNETs, several other observations indicate that signaling pathways involved in DNA damage repair are important in supratentorial PNET development. These include, as described earlier, high-level expression of p53 protein in a large proportion of supratentorial PNETs and development of supratentorial PNET radiation-induced secondary malignancies as well as rare supratentorial PNETs in the setting of multiple sequential malignancies. In addition, we have observed unusual karyotypes indicative of an underlying DNA breakage syndrome in a case of sporadic supratentorial PNET (Fig. 4; L Lafay-Cousin and A Huang, unpublished data). Furthermore, supratentorial PNETs have been reported in two different medulloblastoma mouse models with disruptions of genes that have im-

![Fig. 3. Chart showing regulation of pRB and p53 by the INK4a/ARF tumor suppressor pathway. A simplified schema of the INK4a/pRB/p53 pathway is shown. The INK4a locus encodes p16INK4a and ARF through the use of alternate reading frames. The p16INK4a and related INK4 proteins (INK4b–d) inhibit cdk4/6 activity with consequent hypophosphorylation of pRB. Hypophosphorylated pRB acts with E2F proteins to repress transcription of genes necessary for the G₁–S phase transition. The P14ARF regulates p53 activity by inhibiting MDM2-mediated degradation of p53, allowing p53 to induce cell cycle arrest.](image-url)
Molecular genetics of supratentorial PNETs and pineoblastomas

Important functions in DNA repair, such as p53 or PARP-1 (a DNA damage response gene). The status of the other DNA mismatch repair genes and of PARP-1 in sporadic supratentorial PNET remains to be investigated. It is interesting to note that overlapping losses centering around chromosome 3p21 have been reported in CGH studies of supratentorial PNETs, suggesting potential for hMLH1 loss in a proportion of supratentorial PNETs. The prevalence of PMS2 mutations in hereditary and sporadic supratentorial PNET is also not known, and may prove challenging to determine because multiple PMS2 pseudogenes are located on chromosome 7. Recent studies demonstrate that these pseudogenes on chromosomes 7q13-q12, 7q11, and 7q22 can obscure detection and lead to underdiagnosis of PMS2 mutations. Use of a recently developed PMS2 antibody may help identify patients with putative PMS2 mutations for comprehensive mapping studies in supratentorial PNET.

The hSNF5/INI1 Pathway. Central nervous system atypical rhabdoid teratoid tumors are aggressive lesions that have overlapping clinical, histological, and radiographic features with medulloblastoma or PNET. In particular, the clinical diagnosis and differentiation of supratentorial PNETs from atypical rhabdoid teratoid tumors in a young child have posed significant challenges in the past because both tumors can show predominantly undifferentiated histological features with focal areas of divergent differentiation. A tumor suppressor (hSNF5/INI1) mapping to chromosome 22 has now been identified for atypical rhabdoid teratoid tumors. The hSNF5/1N1 gene product is a component of the SWI/SNF chromatin remodeling complex. Nonrandom association of monosomy on chromosome 22 that typically characterizes atypical rhabdoid teratoid tumors has also been reported for histologically confirmed medulloblastoma and, less frequently, in supratentorial PNET. Studies of INI in medulloblastoma and supratentorial PNET have revealed only very few INI1 mutations, indicating that a distinct chromosome 22 tumor suppressor gene is involved in medulloblastoma and/or supratentorial PNET development. Nonsense mutations resulting in a truncated INI1 gene product were reported in two of 17 supratentorial PNETs in an investigation of hSNF5/INI1 alterations in 229 tumors of various origins. Germ-line INI1 mutations have been reported in rare families with choroid plexus carcinomas, central PNETs, or medulloblastomas presenting in very young children. In addition, de novo constitutional INI1 mutation associated with a supratentorial PNET and a renal rhabdoid tumor has been described.

Molecular Correlates of Disease Phenotypes in Supratentorial PNET

Prognostic roles for erbb2, myc, p53, and Trk receptor expression have been demonstrated in medulloblastoma. The status of erbb2 in supratentorial PNET is not known. Apart from p53, the other markers have only been examined in a handful of supratentorial PNETs collectively with medulloblastoma. Because only very few tumors have been studied with individual markers, their correlation, if any, with clinical phenotypes in supratentorial PNETs cannot be determined based on the current data. It is interesting to note, however, that in studies in which supratentorial PNETs and medulloblastomas have been collectively analyzed for individual markers such as p53 immunopositivity, Notch 2, or hTERT gene activation, the supratentorial PNETs tend to segregate with more aggressive medulloblastoma variants. It will clearly be of interest to determine whether aggressive variants of medulloblastoma share additional overlapping molecular features with supratentorial PNETs.

PINEOBLASTOMAS

Pineoblastomas make up 45 to 50% of pineal parenchymal tumors, and are classified as WHO Grade IV tumors with typical variable reactivity to neuronal and glial markers. Like cerebral supratentorial PNET, pineoblastoma is mainly a childhood disease, with cases only occasionally described in adults. Due to their poorly differentiated histopathological features, they have generally been studied together with other undifferentiated embryonal intracranial PNETs. They have been collectively analyzed with cerebral PNETs in most therapeutic and molecular studies, comprising 20 to 50% of reported supratentorial PNETs in such series. Nevertheless, there is some suggestion that in very young children (<18 months), pineal tumors may occur at a higher frequency than nonpineal lesions. Indeed, tabulation of published cytogenetic data indicates that 40 to 50% of pineoblastomas occur in children less than 1 year old (Table 2).

It is noteworthy that pineoblastomas may exhibit histopathological features indicative of photosensory differentiation ranging from focal expression of retinal S-antigen to characteristic Flexner–Wintersteiner rosettes and fleurettes reminiscent of retinoblastic differentiation (Fig. 5). Embryologically, the pineal gland develops from primitive...
neuroepithelial cells, which line the diencephalic roof and have features of photoreceptor organs, with photosensitivity and neuroendocrine differentiation. These cells are believed to be ontogenetically linked to the photoreceptor cells of the retina. The histological features of pineal and suprasellar PNETs arising in the context of trilateral retinoblastoma (described later), can bear exceptionally close resemblance to retinoblastoma, and this tumor type has been labeled by some as “primary ectopic intracranial retinoblastoma.”4,5 Thus, at least a proportion of pineoblastomas may share ontogenic aspects with precursor cells targeted for transformation during retinoblastoma development.

**Heritable Pineoblastoma**

Tumors presumed to be heritable nonsyndromic pineoblastomas have unknown molecular sources and have been described only rarely. These include cases of pineoblastoma in a mother and a daughter,1,10 sequential development of pineoblastoma and pilocytic astrocytoma in one individual,2 and identical twins with discordant presentation of PNET; one with pineoblastoma and the other with a medulloblastoma.10,16 A rare association of pineoblastoma with familial adenomatous polyposis has also been reported.27

Significantly, pineoblastoma can present in the setting of heritable and sporadic retinoblastoma. Trilateral retinoblastoma, a condition first described in 1971,10 is characterized by an intracranial neuroblastic tumor that typically occurs in the setting of germ-line RB1 gene mutations and heritable disease that manifests as bi- or multifocal disease or family history. Less frequently, trilateral retinoblastoma can manifest with unilateral ocular retinoblastoma.10,22 Rare germ-line mutations of RB manifest as “forme fruste” Rb, with only intracranial PNET, and no ocular tumors.22 Up to 6% of patients with bilateral retinoblastoma and 10% of patients with a family history of these lesions have been reported to harbor an intracranial PNET in one study.12 Trilateral retinoblastoma develops within a median duration of 21 to 23 months from the retinoblastoma diagnosis, has a dismal prognosis, and a 6 month median survival duration following diagnosis of the intracranial tumor.10,12 The bleak outlook warrants measures for reductive therapy and early screening in hereditary retinoblastoma.

Trilateral retinoblastomas with intracranial disease that precede the development of retinoblastoma have been exceptional.9,57 More than 80% of PNETs associated with retinoblastomas are pineal in location, whereas suprasellar or parasellar tumors comprise less than 20% of intracranial tumors in trilateral retinoblastoma. Rare cases of this disease with cerebellar/forth ventricular PNET/medulloblastoma have been reported.3,57 Nevertheless, we are aware of only one case of cerebral PNET reported in association with retinoblastoma. Dorfmuller, et al.,50 described a child in whom a temporal–parietal supratentorial PNET developed 5 years after radiation therapy for a unilateral retinoblastoma. Nevertheless, the atypical location and exceptionally long lag time to development of the intracranial lesions suggests a therapy-related secondary tumor rather than a manifestation of trilateral retinoblastoma.

The observed differences in histological features and location of trilateral retinoblastoma–associated PNET suggest that pineal/suprasellar PNETs and nonpinea cerebral supratentorial PNETs may arise from distinct precursor cell populations. In this respect, it may be relevant that pineal PNETs presenting in very young children are reported to have worse outcomes than cerebral supratentorial PNETs.61,157 Curiously, several therapeutic studies have reported opposite trends in older children, with superior survival rates and lower incidences of metastatic disease in pineal compared with nonpinea supratentorial PNETs.40,47,86 Whether these observed differences reflect true age-related differences in tumor biology or result from earlier clinical manifestations and hence detection of pineal region tumors is not known.

**The RB1 Locus**

The gene of origin for retinoblastoma on chromosome 13q14 (RB1) was one of the first tumor suppressors identified through studies of heritable cancer syndromes.59,100 The pRB pathway has been expertly discussed in several reviews,9,12,154,167 and only its salient features are detailed here and illustrated in Fig. 6.

The RB1 gene product is a nuclear protein that is expressed in many cell types. In addition to a critical role in cell cycle regulation, pRB is also implicated in cellular differentiation, senescence, apoptosis, and embryonic development. One of the best-characterized and critical functions

<table>
<thead>
<tr>
<th>Authors &amp; Year</th>
<th>Tumor Patient Age, Sex</th>
<th>Comment</th>
<th>Karyotype</th>
</tr>
</thead>
<tbody>
<tr>
<td>Griffin, et al., 1988</td>
<td>3 yrs, F</td>
<td>trilat retinoblastoma</td>
<td>42:46;XX,del(1)(p13-21) del(2)(1;?) (p36)</td>
</tr>
<tr>
<td>Sreekantaiah, et al., 1989</td>
<td>2.5 mos, M</td>
<td>primary</td>
<td>46, del(11)(q13.1q13.3)</td>
</tr>
<tr>
<td>Kees, et al., 1994</td>
<td>8 mos, NR</td>
<td>cell line PER-452</td>
<td>iso 17q†</td>
</tr>
<tr>
<td>Agamanolis &amp; Malone, 1995</td>
<td>10 yrs, F</td>
<td>primary</td>
<td>46,XX, +14, -22/46, idem: -20, +mar ‡</td>
</tr>
<tr>
<td>Kees, et al., 1998</td>
<td>11 mos, NR</td>
<td>cell line PER-480</td>
<td>46,XY,del(10)(10;17)(q21,q22-23), der(16)(1;16)(q12;q11.2)</td>
</tr>
<tr>
<td>Roberts, et al., 2001</td>
<td>NR</td>
<td>primary</td>
<td>46,XX, -22</td>
</tr>
<tr>
<td>Batanian, et al., 2003</td>
<td>8 mos, F</td>
<td>complex t(1;11;18)</td>
<td></td>
</tr>
</tbody>
</table>

* NR = not reported.
† N-myc protein overexpression reported.
‡ c-myc protein overexpression reported.
of the pRB protein is that of a transcriptional repressor, a function that is mediated through interactions with different E2F (E2F1–5) protein family members. The E2F proteins normally activate gene transcription by binding to consensus positive regulatory DNA elements in gene promoters. The E2F:RB interactions are tightly controlled by the oncogenic cell cycle–specific proteins; cyclins D1 through D3, cyclin E, and their associated cdks (cdk2/4/6).154 In quiescent cells, hypophosphorylated pRB exists in a complex with E2F4 and other proteins, including p130 and DP1, and acts to recruit chromatin-remodeling proteins such as histone deacetylase to effect “closed chromatin conformation” and consequent gene repression. When normal cells are stimulated with mitogens, hyperphosphorylated pRB generated by increased activity of cyclin:cdk4/6 complexes dissociates from E2F proteins, and enables “switching on” of gene transcription mediated through E2F-binding DNA elements.160 The silencing of genes needed for cells to enter the G1–S phase of the cell cycle is believed to be one of the critical cellular functions of pRB, which is abrogated in cells with genetic or functional loss of this protein.

Structurally, pRB belongs to a family of so-called pocket proteins (other members are the p107 and p130 proteins), characterized by a small “pocket domain” critical for interactions with a variety of cellular proteins, including D-cyclins, associated cdk6, and HDAC1 (a histone deacetylase molecule involved in transcriptional repression by pRB). These proteins share a short conserved LXCXE peptide motif that binds the small pocket domain in pRB and other pRB-related proteins.152 Significantly, similar motifs are found in oncogenic DNA tumor viruses such as E1A, SV40 large T, and the HPV E7 antigens,7,12 which are known to target pRB through the pocket domain during cellular transformation. These observations underscore the importance of pRB transcriptional repressor functions in maintaining normal cellular phenotypes.

Pineoblastoma in Rb Knock-Out Mice

The RB1 gene product has a central function in cell growth regulation, and is ubiquitously expressed in many cell types and tissues. The reason for the narrow spectrum of human cancers seen with germ-line RB1 mutations remains unknown, but is proposed to be related to the intrinsic death resistance phenotypes of retinoblastoma precursor cells.25,36 Surprisingly, several Rb+/− mouse models generated by homologous recombination do not develop retinoblastoma even after prolonged observations, perhaps suggesting differences in human and mouse Rb precursor cells.

In the majority of human trilateral retinoblastomas, the ocular tumors precede pineoblastoma. These observations suggest possible differences in the cell of origin or transformation events required for development of RB and pineoblastoma. The Rb+/− mice developed a high incidence of pituitary neoplasms after a prolonged latency, and RB-deficient embryos showed defective development of the hindbrain due to increased cell death.34 When Rb+/− mice are crossed with p53+/−, a variety of tumors develop, including pineoblastoma. Remarkably, in Rb+/−, p53+/− mice the incidence of pineoblastomas increased to 40%, contrasted with 1% in the Rb+/−, p53+/− mice.19 These observations indicate that functional interactions and cooperative tumorigenic effects of pRB and p53 are important in the development of pineoblastoma. A requirement for concurrent inactivation of p53 and p53 may explain the relatively frequent development of pineal and midbrain PNETs in transgenic mice generated from viral oncogenes (described later) that are known to have pRB and p53 binding activity. Whether both p53 and pRB inactivation is required for development of human pineoblastomas is not known.

Trilateral Rb in Transgenic Mice

Tumors resembling pineoblastomas as well as midbrain PNETs are reported in several retinoblastoma transgenic mouse models driven by different viral oncogenes. In one model in which SV40 large T expression was driven by a Moloney murine sarcoma virus enhancer, pineal hyperplasia developed in adult mice culminating in highly infiltrative midbrain PNET-like tumors with accompanying
Interestingly, there were no retinal tumors; it was reported that the resulting primitive intracranial tumors were found in PNETs associating with retinoblastoma.

Similarly, neurosurgeons report that gene inactivation or alteration can occur in PNETs associated with retinoblastoma.

It is not known whether changes in the pRb protein promoter. Nevertheless, in contrast to pineal PNETs, primitive brain tumors with neuron-specific enolase and S antigen expression developed in the dienencephalon, adjacent to the third ventricle.

The fidelity of viral oncogene–driven transgenic mouse models to human diseases is often limited by lack of promoter specificity. Nonetheless, these studies suggest that loss of pRb can lead to transformation of pineal precursor cells and progenitors in the subventricular germinal matrix. It is likely that loss of pRb and/or p53 occurs in sporadic human pineoblastoma or midbrain PNET; however, the extent of involvement and mechanisms of inactivation remain to be determined.

Molecular Genetic Studies of Pineoblastoma

It is not known whether direct mutations of RB1 or alternate epigenetic mechanisms of RB1 gene inactivation or functional pRB loss occur in sporadic pineoblastoma. Recent observations, which show significantly worse outcomes in patients with pineoblastoma associated with constitutional RB1 defects compared with sporadic pineoblastoma, suggest possible biological differences between these diseases. A number of explanations may underlie these observations, including possible differences in RB1 genotype–phenotype correlations and involvement of distinct loci of origin in these diseases. Alternatively, the more aggressive disease course in pRB-associated pineoblastoma may reflect the greater genomic instability reported to occur with constitutional pRB loss. It is not known whether changes in chromosomes 1q31 and 6p22, which have been reported in 50% of human retinoblastoma, occur in PNETs associated with or not associated with retinoblastoma.

To date only very limited cytogenetic and molecular data are available for this rare tumor. Informative karyotypic studies have been reported for seven cases of primary pineoblastoma; two of these were associated with trilateral retinoblastoma, and two were cell lines (Table 2). As with the cerebral supratentorial PNET, patients with cytogenetically normal karyotypes and isolated monosomy 22 (one case each) were identified. No consistent cytogenetic change can be inferred from these small numbers. Curiously, although pineoblastomas have been linked to hereditary retinoblastoma as part of the trilateral retinoblastoma complex, none of the sporadic cases of pineoblastoma exhibited a visible change in the region of the RB1 locus at chromosome 13q14.

The CGH profiles for pineoblastoma have so far only been reported collectively with cerebral supratentorial PNETs, and therefore pineoblastoma-specific information cannot be separately derived from the publications. Recently, in a CGH study of pineocytomas, intermediate (WHO Grade III) and high-grade (WHO Grade IV [pineoblastoma]) pineal parenchymal tumors were available for this rare tumor. Informative karyotypic studies have been reported for seven cases of primary pineoblastoma; two of these were associated with trilateral retinoblastoma, and two were cell lines (Table 2). As with the cerebral supratentorial PNET, patients with cytogenetically normal karyotypes and isolated monosomy 22 (one case each) were identified. No consistent cytogenetic change can be inferred from these small numbers. Curiously, although pineoblastomas have been linked to hereditary retinoblastoma as part of the trilateral retinoblastoma complex, none of the sporadic cases of pineoblastoma exhibited a visible change in the region of the RB1 locus at chromosome 13q14.

The CGH profiles for pineoblastoma have so far only been reported collectively with cerebral supratentorial PNETs, and therefore pineoblastoma-specific information cannot be separately derived from the publications. Recently, in a CGH study of pineocytomas, intermediate (WHO Grade III) and high-grade (WHO Grade IV [pineoblastoma]) pineal parenchymal tumors were available for this rare tumor. Informative karyotypic studies have been reported for seven cases of primary pineoblastoma; two of these were associated with trilateral retinoblastoma, and two were cell lines (Table 2). As with the cerebral supratentorial PNET, patients with cytogenetically normal karyotypes and isolated monosomy 22 (one case each) were identified. No consistent cytogenetic change can be inferred from these small numbers. Curiously, although pineoblastomas have been linked to hereditary retinoblastoma as part of the trilateral retinoblastoma complex, none of the sporadic cases of pineoblastoma exhibited a visible change in the region of the RB1 locus at chromosome 13q14.
Molecular genetics of supratentorial PNETs and pineoblastomas

Single-gene investigations of pineoblastoma have included five pineal tumors with negative results for p53 and Waf1/p21 gene aberrations. Biegel, et al. reported a missense INI1 mutation in a 7-month-old infant with a histologically confirmed pineoblastoma without rhabdoid features, and with monosomy 22 as the only abnormality. It is not known whether INI1 mutations are more likely to occur in pineoblastomas presenting in very young children with particularly aggressive disease. The recent development of INI1-specific antibodies should facilitate a broader scope of investigations into the genetic and functional role of the INI1 locus in the development of pineoblastoma.

CONCLUSIONS

Molecular genetic studies of supratentorial PNET and pineoblastoma are limited by the rare incidences of these tumors and the ongoing challenges in their histopathological diagnosis. Nonetheless, our review of existing clinical, molecular genetic, and relevant mouse studies implicates a role for the pRB/Ink4/p53 and DNA repair pathways in the development of supratentorial PNETs. Clearly, future concerted collaborative efforts, through dedicated and coordinated clinical, histopathological, and molecular studies are needed to identify the underlying molecular genetic defects involved in supratentorial PNET development. Such studies will be crucial for the development of appropriate disease models and more effective treatment regimens for these tumors.

References


42. Coskun V, Luskin MB: The expression pattern of the cell cycle inhibitor p19INK4d, a p16-related inhibitor specific to CDK6 and CDK7, is developmentally normal but susceptible to spontaneous and acquired mutations causing a distinctive childhood cancer. *Am J Hum Genet* 74:954–964, 2004


Molecular genetics of supratentorial PNETs and pineoblastomas

77. Hu QL, Dyson N, Harlow E: The regions of the retinoblastoma protein needed for binding to adenovirus E1A or SV40 large T antigen are common sites for mutations. EMBO J 9: 1147–1155, 1990


122. Paulino AC: Trilateral retinoblastoma: is the location of the intracranial tumor important? *Cancer* **86**:135–141, 1999


icas of 58 pediatric brain tumors. *Cancer Genet Cyto
genet* **131**:1–12, 2001


133. Rorke LB: Classification and grading of childhood brain tu

134. Rorke LB, Biegel JA: Atypical teratoid/rhabdoid tumors, in Klei


137. Scheretz M. H. Li, et al.


Manuscript received October 7, 2005. Accepted in final form October 20, 2005. Financial support was received from B.R.A.I.N. Child and is gratefully acknowledged. Dr. Huang is supported by a clinician scientist award from Cancer Care Ontario, Eli Lilly, and the Canadian Institute of Health Research.

Address reprint requests to: Annie Huang, M.D., Ph.D., Division of Hematology-Oncology, Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8 Canada. email: annie.huang@sickkids.ca.